Literature DB >> 9707312

In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.

T Alarcón1, D Domingo, I Sánchez, J C Sanz, M J Martínez, M López-Brea.   

Abstract

The aim of this study was to determine the in vitro activity of ranitidine, ebrotidine, bismuth citrate, omeprazole, and lansoprazole against 113 clinical isolates of Helicobacter pylori cultured from gastric biopsies. An agar dilution method using Mueller-Hinton agar plus 7%, horse blood, an inoculum of 10(6) cfu/spot, and incubation in a CO2 incubator for 2 to 5 days was used. The minimum inhibitory concentrations for 50 and 90% of the isolates tested, respectively, were as follows: ranitidine, 1024 and 1024 mg/l; ebrotidine, 64 and 256 mg/l; bismuth citrate, 1 and 4 mg/l; omeprazole, 16 and 16 mg/l; and lansoprazole, 1 and 1 mg/l. Ebrotidine was more active than ranitidine, and lansoprazole was the most active compound against the Helicobacter pylori isolates tested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707312     DOI: 10.1007/bf01699986

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine.

Authors:  J Piotrowski; E Piotrowski; A Slomiany; B L Slomiany
Journal:  J Physiol Pharmacol       Date:  1995-12       Impact factor: 3.011

Review 2.  Campylobacter pylori: its link to gastritis and peptic ulcer disease.

Authors:  B J Marshall
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

Review 3.  The actions of bismuth in the treatment of Helicobacter pylori infection.

Authors:  J R Lambert; P Midolo
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

Review 4.  Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors.

Authors:  M G Korman
Journal:  Scand J Gastroenterol Suppl       Date:  1996

5.  Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors:  M Nakao; M Tada; K Tsuchimori; M Uekata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 6.  Proton pump inhibitors: new drugs and indications.

Authors:  J M Mears; B Kaplan
Journal:  Am Fam Physician       Date:  1996-01       Impact factor: 3.292

7.  Colloidal bismuth subcitrate and omeprazole inhibit alcohol dehydrogenase mediated acetaldehyde production by Helicobacter pylori.

Authors:  R P Roine; K S Salmela; J Höök-Nikanne; T U Kosunen; M Salaspuro
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

8.  Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies.

Authors:  W Dickey; B D Kenny; J B McConnell
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

Review 9.  Ebrotidine.

Authors:  S S Patel; M I Wilde
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 10.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

View more
  2 in total

Review 1.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.